- Date 28 Sep 2020
Nuformix a pharmaceutical development company focused on unlocking the therapeutic potential and value of known
drugs to develop novel medicines to provide enhanced benefit, announces it has signed an exclusive
option agreement with Oxilio Ltd (“Oxilio”)
You might also be interested in these articles
Cambridge Science Park Director Jane Hutchins is now a Board Director of UKSPA (United Kingdom Science Park Association).
Thu 16 Jan 2025
Cambridge Science Park Director Jane Hutchins is now a Board Director of UKSPA (United Kingdom Science Park Association).
Thu 16 Jan 2025
Cambridge Science Centre Welcomes Rebecca Porter as New CEO
Wed 11 Dec 2024
Join an ambitious, supportive community of world-class scientists, engineers and entrepreneurs
Read more